INM-089 IVT formulation selected for continued development Demonstrated successful delivery at doses up to 10 times the projected therapeutic level, indicating a favorable pharmacokinetic profile and a significant safety margin… Read More
Clinical trials are crucial for making sure that new drugs, treatments, and medical devices are safe and effective. But people living in rural and remote areas, such as northern BC,… Read More
The International Society for Cell & Gene Therapy (ISCT) is delighted to announce the appointment of Phil Vanek, PhD, as the new ISCT Chief Commercialization Officer (CCO), effective January 1, 2025,… Read More
VANCOUVER, BC – Acuitas’ Chief Scientific Officer, Dr. Ying Tam, collaborated with scientists from the Children’s Hospital of Philadelphia and Perelman School of Medicine to determine whether messenger RNA lipid… Read More
JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years JOURNAVX is an effective… Read More
